In last trading session, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) saw 0.47 million shares changing hands with its beta currently measuring 0.10. Company’s recent per share price level of $0.33 trading at -$0.02 or -5.37% at ring of the bell on the day assigns it a market valuation of $7.86M. That closing price of CYCC’s stock is at a discount of -11972.73% from its 52-week high price of $39.84 and is indicating a premium of 24.24% from its 52-week low price of $0.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.64 million shares which gives us an average trading volume of 1.43 million if we extend that period to 3-months.
For Cyclacel Pharmaceuticals Inc (CYCC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Upright in the red during last session for losing -5.37%, in the last five days CYCC remained trading in the red while hitting it’s week-highest on Wednesday, 06/25/25 when the stock touched $0.33 price level, adding 19.02% to its value on the day. Cyclacel Pharmaceuticals Inc’s shares saw a change of -98.70% in year-to-date performance and have moved -2.90% in past 5-day. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) showed a performance of -81.09% in past 30-days. Number of shares sold short was 0.6 million shares which calculate 0.26 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 1 to the stock, which implies a rise of 67.0% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 1. It follows that stock’s current price would drop -203.03% in reaching the projected high whereas dropping to the targeted low would mean a loss of -203.03% for stock’s current value.
Cyclacel Pharmaceuticals Inc (CYCC) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 57.31% during past 5 years.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Insiders are in possession of 61.49% of company’s total shares while institution are holding 6.64 percent of that, with stock having share float percentage of 17.24%. Investors also watch the number of corporate investors in a company very closely, which is 6.64% institutions for Cyclacel Pharmaceuticals Inc that are currently holding shares of the company.
On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Apr 30, 2025 , the former fund manager was holding 3.24 shares of worth $1072.0 or 0.01% of the total outstanding shares. The later fund manager was in possession of 362.0 shares on Mar 31, 2025 , making its stake of worth around $119.0 in the company or a holder of 0.00% of company’s stock.
